Approximately 75% of breast cancers that express estrogen receptor (ER) and/or progesterone receptor (PR) but not human epidermal growth factor receptor 2 (HER2) belong to the HR-positive (HR+)/HER2-negative (HER2−) breast cancer. This evidence concerns the gene ESR1 and breast cancer.